^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Cervical Cancer |
| Drug: | balstilimab (AGEN2034) (PD1 inhibitor) + zalifrelimab (UGN-301) (CTLA4 antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study
Published date:
12/21/2021
Excerpt:
Patients were intravenously dosed with balstilimab 3 mg/kg once every 2 weeks and zalifrelimab 1 mg/kg...The ORRs were 32.8% and 9.1% in patients with programmed death ligand-1–positive and programmed death ligand-1–negative tumors, respectively.
DOI:
10.1200/JCO.21.02067 Journal of Clinical Oncology
Trial ID:
